Dose-Limiting Pulmonary Toxicity in a Phase 1/2 Study of Radiation and Chemotherapy with Ipilimumab Followed by Nivolumab for Patients With Stage 3 Unresectable Non-Small Cell Lung CancerCasey Liveringhouse, Bradford A. Perez, Kujtim Latifi et al.|International Journal of Radiation Oncology*Biology*Physics|2023Cited by 18
Nivolumab and stereotactic radiosurgery for patients with breast cancer brain metastases: long-term results and biomarker analysis from a non-randomized, open-label, phase Ib studyKamran A. Ahmed, Hyo S. Han, Michelle DeJesus et al.|Journal for ImmunoTherapy of Cancer|2025Cited by 7